Personalized workflow to identify optimal T-cell epitopes for peptide-based vaccines against COVID-19

Traditional vaccines against viruses are designed to target their surface proteins, i.e., antigens, which can trigger the immune system to produce specific antibodies to capture and neutralize the viruses. However, viruses often evolve quickly, and their antigens are prone to mutations to avoid recognition by the antibodies (antigenic drift). This limitation of the antibody-mediated immunity could be addressed by the T-cell mediated immunity, which is able to recognize conserved viral HLA peptides presented on virus-infected cells. Thus, by targeting conserved regions on the genome of a virus, T-cell epitope-based vaccines are less subjected to mutations and may work effectively on different strains of the virus. Here we propose a personalized workflow to identify an optimal set of T-cell epitopes based on the HLA alleles and the immunopeptidome of an individual person. Specifically, our workflow trains a machine learning model on the immunopeptidome and then predicts HLA peptides from conserved regions of a virus that are most likely to trigger responses from the person T cells. We applied the workflow to identify T-cell epitopes for the SARS-COV-2 virus, which has caused the recent COVID-19 pandemic in more than 100 countries across the globe.

[1]  Shibo Jiang,et al.  Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design , 2006, Journal of Virology.

[2]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[3]  Jiandong Shi,et al.  Inferring Protective CD8+ T-Cell Epitopes for NS5 Protein of Four Serotypes of Dengue Virus Chinese Isolates Based on HLA-A, -B and -C Allelic Distribution: Implications for Epitope-Based Universal Vaccine Design , 2015, PloS one.

[4]  Sri H. Ramarathinam,et al.  A subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligands , 2018, Science Immunology.

[5]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[6]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[7]  D. van Baarle,et al.  T Cell Responses to Viral Infections – Opportunities for Peptide Vaccination , 2014, Front. Immunol..

[8]  Shibo Jiang,et al.  The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.

[9]  G. Gao,et al.  Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development , 2011, Experimental biology and medicine.

[10]  S. Gilbert,et al.  T‐cell‐inducing vaccines – what’s the future , 2012, Immunology.

[11]  Fei Deng,et al.  Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin , 2020, bioRxiv.

[12]  Arafat Rahman Oany,et al.  Design of an epitope-based peptide vaccine against spike protein of human coronavirus: an in silico approach , 2014, Drug design, development and therapy.

[13]  Ngoc Hieu Tran,et al.  Deep learning enables de novo peptide sequencing from data-independent-acquisition mass spectrometry , 2018, Nature Methods.

[14]  P. Gendron,et al.  Noncoding regions are the main source of targetable tumor-specific antigens , 2018, Science Translational Medicine.

[15]  P. Doherty,et al.  Recalling the Future: Immunological Memory Toward Unpredictable Influenza Viruses , 2019, Front. Immunol..

[16]  P. Cochat,et al.  Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[17]  Baozhen Shan,et al.  De novo peptide sequencing by deep learning , 2017, Proceedings of the National Academy of Sciences.

[18]  Xin Chen,et al.  Personalized deep learning of individual immunopeptidomes to identify neoantigens for cancer vaccines , 2019, Nature Machine Intelligence.